Arecor Therapeutics (LSE:AREC) Research & Development: £2.69 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:AREC Arecor Therapeutics PLC LSE:AREC
37 GF Score
Price £0.61
GF Value £0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Research & Development?

Arecor Therapeutics LSE:AREC -3.94% 37 Research & Development is £2.69 Mil as of Dec. 2025. GuruFocus rates LSE:AREC with a GF Score™ of 37/100 and a GF Value™ of £0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Arecor Therapeutics's Research & Development for the six months ended in Dec. 2025 was £1.42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £2.69 Mil.

Arecor Therapeutics  (LSE:AREC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arecor Therapeutics Research & Development Related Terms

Arecor Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Arecor Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Research & Development Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 5.39 8.61 5.40 3.04 2.69

Arecor Therapeutics Semi-Annual Data
May17 May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 1.73 1.32 1.28 1.42
LSE:AREC
37GF Score
Arecor Therapeutics PLC LSE:AREC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arecor Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £2.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £2.69 Mil mean?
Arecor Therapeutics (LSE:AREC) has a Research & Development of £2.69 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Arecor Therapeutics and its competitors.
Is Arecor Therapeutics' Research & Development too high?
Arecor Therapeutics' current Research & Development is £2.69 Mil. Overall, Arecor Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Research & Development compare to VRTX and REGN?
Arecor Therapeutics' Research & Development of £2.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arecor Therapeutics and its competitors. Arecor Therapeutics's current Research & Development is £2.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arecor Therapeutics (LSE:AREC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.44, compared to a current price of £0.61 — trading 38.6% above its estimated fair value. The current Research & Development is £2.69 Mil. Arecor Therapeutics' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arecor Therapeutics (LSE:AREC), the current Research & Development is £2.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of £0.61 is trading 38.6% above its estimated GF Value™ of £0.44. GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.

Key valuation signals for LSE:AREC:

  • Research & Development: £2.69 Mil
  • GF Value™: £0.44 vs. price of £0.61 (38.6% above fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arecor Therapeutics Business Description

Other Exchanges 6UI:Germany
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
37GF Score

Get the complete analysis for LSE:AREC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.61
Price
£0.44
GF Value